Publications
Detailed Information
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Schuler, M. | - |
dc.contributor.author | Yang, J. C. -H. | - |
dc.contributor.author | Park, K. | - |
dc.contributor.author | Kim, J. -H. | - |
dc.contributor.author | Bennouna, J. | - |
dc.contributor.author | Chen, Y. -M. | - |
dc.contributor.author | Chouaid, C. | - |
dc.contributor.author | De Marinis, F. | - |
dc.contributor.author | Feng, J. -F. | - |
dc.contributor.author | Grossi, F. | - |
dc.contributor.author | Kim, D. -W. | - |
dc.contributor.author | Liu, X. | - |
dc.contributor.author | Lu, S. | - |
dc.contributor.author | Strausz, J. | - |
dc.contributor.author | Vinnyk, Y. | - |
dc.contributor.author | Wiewrodt, R. | - |
dc.contributor.author | Zhou, C. | - |
dc.contributor.author | Wang, B. | - |
dc.contributor.author | Chand, V. K. | - |
dc.contributor.author | Planchard, D. | - |
dc.date.accessioned | 2020-04-27T11:14:01Z | - |
dc.date.available | 2020-04-27T11:14:01Z | - |
dc.date.created | 2018-08-27 | - |
dc.date.issued | 2016-03 | - |
dc.identifier.citation | Annals of Oncology, Vol.27 No.3, pp.417-423 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.other | 47281 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165302 | - |
dc.description.abstract | Afatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade with afatinib plus paclitaxel has superior outcomes versus switching to chemotherapy alone in patients acquiring resistance to erlotinib/gefitinib and afatinib monotherapy. Patients with relapsed/refractory disease following a parts per thousand yen1 line of chemotherapy, and whose tumors had progressed following initial disease control (a parts per thousand yen12 weeks) with erlotinib/gefitinib and thereafter afatinib (50 mg/day), were randomized 2:1 to receive afatinib plus paclitaxel (40 mg/day; 80 mg/m(2)/week) or investigator's choice of single-agent chemotherapy. The primary end point was progression-free survival (PFS). Other end points included objective response rate (ORR), overall survival (OS), safety and patient-reported outcomes. Two hundred and two patients with progressive disease following clinical benefit from afatinib were randomized to afatinib plus paclitaxel (n = 134) or single-agent chemotherapy (n = 68). PFS (median 5.6 versus 2.8 months, hazard ratio 0.60, P = 0.003) and ORR (32.1% versus 13.2%, P = 0.005) significantly improved with afatinib plus paclitaxel. There was no difference in OS. Global health status/quality of life was maintained with afatinib plus paclitaxel over the entire treatment period. The median treatment duration was 133 and 51 days with afatinib plus paclitaxel and single-agent chemotherapy, respectively; 48.5% of patients receiving afatinib plus paclitaxel and 30.0% of patients receiving single-agent chemotherapy experienced drug-related grade 3/4 adverse events. Treatment-related adverse events were consistent with those previously reported with each agent. Afatinib plus paclitaxel improved PFS and ORR compared with single-agent chemotherapy in patients who acquired resistance to erlotinib/gefitinib and progressed on afatinib after initial benefit. LUX-Lung 5 is the first prospective trial to demonstrate the benefit of continued ErbB targeting post-progression, versus switching to single-agent chemotherapy. NCT01085136 (clinicaltrials.gov). | - |
dc.language | 영어 | - |
dc.publisher | Oxford University Press | - |
dc.title | Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.identifier.doi | 10.1093/annonc/mdv597 | - |
dc.citation.journaltitle | Annals of Oncology | - |
dc.identifier.wosid | 000371691600009 | - |
dc.identifier.scopusid | 2-s2.0-84959893848 | - |
dc.citation.endpage | 423 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 417 | - |
dc.citation.volume | 27 | - |
dc.identifier.sci | 000371691600009 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, D. -W. | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | TYROSINE KINASE INHIBITORS | - |
dc.subject.keywordPlus | ACQUIRED-RESISTANCE | - |
dc.subject.keywordPlus | CLINICAL-TRIALS | - |
dc.subject.keywordPlus | EGFR MUTATIONS | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | BIBW 2992 | - |
dc.subject.keywordPlus | ERLOTINIB | - |
dc.subject.keywordPlus | GEFITINIB | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | DISCONTINUATION | - |
dc.subject.keywordAuthor | afatinib | - |
dc.subject.keywordAuthor | paclitaxel | - |
dc.subject.keywordAuthor | NSCLC | - |
dc.subject.keywordAuthor | squamous cell | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.